Ongoing Clinical Trials for Bacterial Endocarditis
Currently, there is 1 ongoing clinical trial focused on bacterial endocarditis, also known as infective endocarditis. This trial is investigating whether oral antibiotics can be as effective as intravenous antibiotics for treating this serious heart infection. The study is being conducted in Spain and compares oral amoxicillin treatment with traditional intravenous antibiotic therapy for patients who have already received initial treatment for infective endocarditis. (Also known as: Infective Endocarditis)
Clinical trial locations
Study Comparing Oral Amoxicillin to Outpatient IV Antibiotics for Patients with Infective Endocarditis
This clinical trial is examining whether patients with infective endocarditis can be effectively treated with oral antibiotics taken by mouth instead of continuing to receive antibiotics through an intravenous line. The study specifically tests oral amoxicillin against traditional intravenous antibiotic treatment administered in an outpatient setting.
Main Inclusion Criteria:
- Patients must be 18 years of age or older
- Diagnosis of infective endocarditis affecting the left side of the heart, either on a natural or artificial heart valve, caused by bacteria that respond to treatment
- Must have already received at least 10 days of appropriate intravenous antibiotic treatment (or at least one week after heart valve surgery if applicable)
- Body temperature below 38.0°C for more than two days
- C-reactive protein levels (a marker showing inflammation in the body) must have decreased to less than 25% of the highest value or be below 20 mg/L
- White blood cell count must be less than 15 billion per liter
- No signs of abscess (a pocket of pus) in the heart as confirmed by an echocardiogram (heart ultrasound)
- Recent echocardiogram performed, preferably within 48 hours of study enrollment
Main Exclusion Criteria:
- Patients who do not have a confirmed diagnosis of infective endocarditis
- Patients outside the specified age range for the study
- Patients who do not meet the clinical trial group requirements
- Patients who are not part of the vulnerable population selected for this research
Trial Focus and Goals:
The primary goal of this study is to determine whether oral antibiotic treatment is as effective as intravenous antibiotic treatment for patients with infective endocarditis. Researchers will monitor participants over a six-month period to observe important outcomes including unplanned hospitalizations, death, need for additional heart surgery, or return of the infection. The study will also evaluate quality of life, patient satisfaction, and the costs associated with each treatment approach. This information will help doctors understand if oral treatment could be a simpler, more convenient option for patients who have already completed the initial phase of intravenous therapy.
Investigational Drugs:
The trial compares two antibiotic approaches. The oral treatment arm uses amoxicillin, a penicillin-type antibiotic taken as tablets at a dose of 1000 mg as prescribed by the study protocol. Amoxicillin works by preventing bacteria from building their cell walls, which leads to their destruction. The comparison arm receives parenteral antibiotic treatment, which involves antibiotics delivered through a vein, typically using medications like ceftriaxone, a cephalosporin antibiotic that works similarly by disrupting bacterial cell wall formation.
Throughout the study, participants will be regularly monitored to assess their health status, response to treatment, and any complications. The research team will track important health markers and conduct follow-up assessments to ensure patient safety and collect data on treatment effectiveness.
Summary
This single ongoing trial for bacterial endocarditis represents an important investigation into treatment options for this serious heart infection. The study, conducted in Spain, addresses a significant clinical question: whether patients who have already received initial intravenous antibiotic treatment can safely transition to oral antibiotics for the remainder of their therapy. This approach could potentially reduce the burden of prolonged intravenous treatment, minimize complications associated with intravenous lines, improve patient quality of life, and reduce healthcare costs while maintaining effective treatment outcomes. The focus on amoxicillin, a well-established and widely available antibiotic, suggests practical applicability if the oral approach proves successful.
